Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance

HLS Therapeutics

15/05/2026 12:14

Overview

Canada pharma firm's Q1 revenue rose 2% yr/yr, driven by Vascepa net sales growth

Adjusted EBITDA fell yr/yr as company increased investment in NILEMDO launch

Company reaffirmed 2026 financial guidance and reported strong cash generation, debt reduction

Outlook

HLS reaffirms 2026 revenue guidance of $56–60 mln

Company maintains 2026 Adjusted EBITDA outlook at $18.5–21 mln

Company says future results could be impacted by exchange rate volatility

Result Drivers

VASCEPA GROWTH - Vascepa net sales rose 15% yr/yr, reflecting sustained demand and commercial team changes made in 2025

NILEMDO LAUNCH INVESTMENT - Adjusted EBITDA declined yr/yr due to increased commercial investment ahead of NILEMDO launch

Company press release: ID:nCNWsZxcxa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$12.9 mln
$13.20 mln (2 Analysts)
Q1 EPS
$0.07


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for HLS Therapeutics Inc is C$7.00, about 49.9% above its May 14 closing price of C$4.67

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)